The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).
 
Ziad Bakouny
No Relationships to Disclose
 
Sarah Abou Alaiwi
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Ronan Flippot
No Relationships to Disclose
 
Pier Vitale Nuzzo
No Relationships to Disclose
 
Dominick Bossé
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Pfizer
 
Xiao X. Wei
Honoraria - OncLive
Travel, Accommodations, Expenses - Corvus Pharmaceuticals
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Seattle Genetics/Astellas (Inst)
 
Lauren Christine Harshman
Consulting or Advisory Role - Bayer; Corvus Pharmaceuticals; Exelixis; Genentech; KEW; Merck; Novartis; Pfizer; Theragene
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst); Sotio (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bayer
 
Sabina Signoretti
No Relationships to Disclose
 
David J. Kwiatkowski
Consulting or Advisory Role - AstraZeneca; Genentech/Roche
Research Funding - AADi
 
Toni K. Choueiri
Honoraria - Alexion Pharmaceuticals; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; PER; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)